BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...see Emerging Company Profile: “Applying AAV9 Across the CNS”).Conroy’s Cowen presentation lifts Exact Sciences Cancer screening company Exact Sciences...
...Conroy told the Cowen Liquid Biopsy Summit. The stock rose $19.96 (27%) to $94.04, giving Exact Sciences...
BioCentury | Aug 27, 2020
Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round

...estimated adherence rates of 33-43% for stool-based tests.Exact Sciences Corp....
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...committee meeting to discuss the application. Trio of studies back Exact’s personalized breast cancer test Exact Sciences Corp....
... SubQ ofatumumab, subcutaneous ofatumumab ATB-346 maralixibat (SHP625, lum001) Oncotype DX breast cancer assay BeiGene Ltd. Novartis AG Antibe Therapeutics Inc. Mirum Pharmaceuticals Inc. Exact Sciences Corp. Merck...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

...or non-urgent and dosing should not be delayed for a significant period of time.” Separately, Exact Sciences Corp....
...COVID-19.” In February, the colorectal cancer testing company had projected 2020 revenues of $1.61-$1.645 billion. Exact Sciences...
...Brand), IONIS-SMNRx (Compound #), ISIS-SMNRx (Former compound #), nusinersen (Generic), Spinraza (Informal) GeNeuro S.A. Provention Bio Inc. Biogen Inc. Exact Sciences Corp. COVID-19...
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

...coverage by conducting prospective trials demonstrating clinical utility. Genomic Health Inc., which was acquired by Exact Sciences...
BioCentury | Sep 27, 2019
Company News

FDA broadens approval for Exact's Cologuard

...FDA approved colorectal cancer screening test Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) for average-risk adults ages 45 and...
...of the test. Hongjiang Li, Staff Writer Cologuard (Brand), Stool DNA colorectal cancer screening assay (Informal), Cologuard (Other) Exact Sciences Corp....
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

...Other) Cologuard (Brand), Stool DNA colorectal cancer screening assay (Informal), Cologuard (Other) Bayer AG GW Pharmaceuticals plc Bavarian Nordic A/S Exact Sciences Corp. Evotec...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...Mass.) hired Maneesh Arora as president and CEO. Arora, who was COO and direct at Exact Sciences Corp....
BioCentury | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

...a play to expand its international reach, its position with payers and its sales force, Exact Sciences...
...deal valued at $2.8 billion. The deal also helps accelerate a move into diagnostics by Exact Sciences Corp....
...cancer assay Oncotype DX colon cancer assay Oncotype DX prostate cancer assay, Oncotype DX Genomic Prostate Score test Exact Sciences Corp. Genomic...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...quarter up 45%, at HK$117.8 billion ($15.1 billion). Following Hansoh in the large-cap tier was Exact Sciences...
...Boulder, Colo. ArQule Inc. (NASDAQ:ARQL), Burlington, Mass. American Society of Clinical Oncology (ASCO), Alexandria, Va. Exact Sciences Corp....
...receptor tyrosine kinase Meredith Durkin Wolfe, Associate Editor, Data & Analytics Adaptive Biotechnologies Corp. Alkermes plc ArQule Inc. Array BioPharma Inc. Exact Sciences Corp. Hansoh...
Items per page:
1 - 10 of 242
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...see Emerging Company Profile: “Applying AAV9 Across the CNS”).Conroy’s Cowen presentation lifts Exact Sciences Cancer screening company Exact Sciences...
...Conroy told the Cowen Liquid Biopsy Summit. The stock rose $19.96 (27%) to $94.04, giving Exact Sciences...
BioCentury | Aug 27, 2020
Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round

...estimated adherence rates of 33-43% for stool-based tests.Exact Sciences Corp....
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...committee meeting to discuss the application. Trio of studies back Exact’s personalized breast cancer test Exact Sciences Corp....
... SubQ ofatumumab, subcutaneous ofatumumab ATB-346 maralixibat (SHP625, lum001) Oncotype DX breast cancer assay BeiGene Ltd. Novartis AG Antibe Therapeutics Inc. Mirum Pharmaceuticals Inc. Exact Sciences Corp. Merck...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

...or non-urgent and dosing should not be delayed for a significant period of time.” Separately, Exact Sciences Corp....
...COVID-19.” In February, the colorectal cancer testing company had projected 2020 revenues of $1.61-$1.645 billion. Exact Sciences...
...Brand), IONIS-SMNRx (Compound #), ISIS-SMNRx (Former compound #), nusinersen (Generic), Spinraza (Informal) GeNeuro S.A. Provention Bio Inc. Biogen Inc. Exact Sciences Corp. COVID-19...
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

...coverage by conducting prospective trials demonstrating clinical utility. Genomic Health Inc., which was acquired by Exact Sciences...
BioCentury | Sep 27, 2019
Company News

FDA broadens approval for Exact's Cologuard

...FDA approved colorectal cancer screening test Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) for average-risk adults ages 45 and...
...of the test. Hongjiang Li, Staff Writer Cologuard (Brand), Stool DNA colorectal cancer screening assay (Informal), Cologuard (Other) Exact Sciences Corp....
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

...Other) Cologuard (Brand), Stool DNA colorectal cancer screening assay (Informal), Cologuard (Other) Bayer AG GW Pharmaceuticals plc Bavarian Nordic A/S Exact Sciences Corp. Evotec...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...Mass.) hired Maneesh Arora as president and CEO. Arora, who was COO and direct at Exact Sciences Corp....
BioCentury | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

...a play to expand its international reach, its position with payers and its sales force, Exact Sciences...
...deal valued at $2.8 billion. The deal also helps accelerate a move into diagnostics by Exact Sciences Corp....
...cancer assay Oncotype DX colon cancer assay Oncotype DX prostate cancer assay, Oncotype DX Genomic Prostate Score test Exact Sciences Corp. Genomic...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...quarter up 45%, at HK$117.8 billion ($15.1 billion). Following Hansoh in the large-cap tier was Exact Sciences...
...Boulder, Colo. ArQule Inc. (NASDAQ:ARQL), Burlington, Mass. American Society of Clinical Oncology (ASCO), Alexandria, Va. Exact Sciences Corp....
...receptor tyrosine kinase Meredith Durkin Wolfe, Associate Editor, Data & Analytics Adaptive Biotechnologies Corp. Alkermes plc ArQule Inc. Array BioPharma Inc. Exact Sciences Corp. Hansoh...
Items per page:
1 - 10 of 242